Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Theracos, Inc.

Shanghai Zelgen Pharma.tech Co., Ltd.

Suzhou Zelgen Biopharmaceutical Co., Ltd.

Zelin Sheng

Binhua Lv

Lili Zhang

Brian Seed

Min Xu

Tao Han

Yan Feng

Yuanwei Chen

Dawei Cui

Michael J Hadd

Ge Xu

Baihua Xu

Jiyan Du

Yuelin Wu

Chengwei Li

Huawei Cheng

Congna Wang

Benwen Cao

Lianjun Liu

Runqing Wang

Peizhong Ni

Ruifeng Liu

Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and the use thereof are described. Compounds of the present invention have a structure represented by formula (I). Further disclosed are preparation methods for said compounds, and the use of said compounds as KRASinhibitors. The compounds have an excellent ability to selectively inhibit KRAS, improved pharmacodynamic and pharmacokinetic performance, and reduced toxic side effects. 

Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof

Disclosed are deuterated chenodeoxycholic acid derivatives and pharmaceutical compositions containing the deuterated chenodeoxycholic acid derivatives. In particular, disclosed is a deuterated chenodeoxycholic acid derivative of formula (I), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the same. The deuterated chenodeoxycholic acid derivatives of formula (I) can be used to treat and/or prevent diseases related to the farnesoid X receptor (FXR) and/or G-protein coupled bile acid receptor, such as nonalcoholic steatohepatitis, nonalcoholic fatty liver diseases, gallstones, primary biliary cirrhosis, and cirrhosis.

Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof

The present invention relates to a deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing the same. Specifically provided are a deuterated phenyl amino pyrimidine compound as represented by formula (I), and pharmaceutical composition containing the compound, or polymorph, pharmaceutically acceptable salt, hydrate or solvate thereof. The compound of the present invention can treat and/or prevent JAK kinase-related diseases, such as bone marrow proliferative disease, cancer, immunologic diseases and the like.

Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing the same

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

Benzylic glycoside derivatives and methods of use

Growing community of inventors

Jiangsu, China

Zelin Sheng